Building Bridges Between Academic Drug Discovery and Industry

Dr Andrew Napper, Head of the High-Throughput Screening/Drug Discovery Lab at Alfred I. duPont Hospital for Children and Chair of the SLAS Academic Drug Discovery Special Interest Group, describes how the group aims to enable greater interaction between academia, pharmaceutical research companies, suppliers and other technical companies.